Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Regimen shows promise as salvage for classical HL

Publish date:: February 22, 2019

Key clinical point: Brentuximab vedotin plus ifosfamide, gemcitabine, and vinorelbine (BV-IGEV) appears effective as salvage for patients with relapsed/refractory classical Hodgkin lymphoma.

Major finding: Of 28 patients, 27 responded to BV-IGEV.

Study details: A retrospective study of 28 patients.

Disclosures: The authors reported having no conflicts of interest.

Citation:

Abuelgasim KA et al. Bone Marrow Transplant. 2019 Jan 30. doi: 10.1038/s41409-019-0454-z.

This Week's Must Reads

Study IDs factors tied to improved survival in Burkitt lymphoma,

Clinical model helps predict outcomes in r/r DLBCL,

Incidence of R/R DLBCL lower than expected in population-based study,

Fragmentation of sickle cell disease care starts in young adulthood,

Care coordination, equity can eliminate disparities for nonwhite patients with DLBCL,

Must Reads in Hodgkin Lymphoma

Worse PFS when radiation is withheld in early-stage Hodgkin lymphoma,

Cell count ratios appear to predict thromboembolism in lymphoma,

Regimen shows promise as salvage for classical HL,

Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.